Allogene
1 known investors
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- Allogene reports 31% response rate in renal cancer trial By Investing.cominvesting.com · 2026
- Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.comca.investing.com · 2026
- Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisionsfinance.yahoo.com · 2026